​

Iterum Therapeutics Stock (NASDAQ:ITRM)

RevenueOwnershipFinancialsChartTranscripts
Iterum Therapeutics by TradingView

Previous Close

$0.03

52W Range

$0.03 - $1.42

50D Avg

$0.21

200D Avg

$0.52

Market Cap

$1.60M

Avg Vol (3M)

$16.33M

Beta

3.01

Div Yield

-

ITRM Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IE

Employees

9

IPO Date

May 25, 2018

Website

ITRM Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceSep 25
Operating Segments$390.00K

Fiscal year ends in Dec 24 | Currency in USD

ITRM Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-18.70M$-47.47M$-30.38M
Net Income$-24.77M$-38.37M$-44.43M
EBITDA$-18.70M$-34.58M$-39.97M
Basic EPS$-1.26$-2.96$-3.63
Diluted EPS$-1.26$-2.96$-3.63

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 14, 25 | 8:30 AM
Q2 25Aug 05, 25 | 8:30 AM
Q1 25May 13, 25 | 8:30 AM

Peer Comparison

TickerCompany
PLURPluri Inc.
INTSIntensity Therapeutics, Inc.
IBIOiBio, Inc.
TAOXTAO Synergies Inc.
RLYBRallybio Corporation
KLTOKlotho Neurosciences, Inc.
QTTBQ32 Bio Inc.
BOLDBoundless Bio, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
ANTXAN2 Therapeutics, Inc.